Treatment with low-doses of the anti-inflammatory drug methotrexate failed to reduce the levels of IL-1β, IL-6 or C-reactive protein (CRP), and CV events in patients with stable atherosclerosis and high CV risk [7]. Here, CRP is linked to atherosclerosis.